Azithromycin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Azithromycin: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Azithromycin is a macrolide antibiotic originally used for bacterial infections such as streptococcal infection, bacterial pneumonia, conjunctivitis and several sexually transmitted infections. The TxGNN model predicts it may be effective for hyperamylasemia, but no clinical trials and no publications support this prediction, so it rests on a graph-based score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Streptococcal infection, bacterial pneumonia, staphylococcal infection and other bacterial infections (no approved indication text is available in the Singapore licence records) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 16 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, azithromycin is a macrolide antibiotic, its efficacy in bacterial infections is well established, and no mechanistic link to hyperamylasemia can be established from the data compiled for this report.
Hyperamylasemia is a laboratory finding (raised blood amylase) rather than an infection. The data provides no antibacterial or immunomodulatory rationale for treating it. The very high score most likely reflects the structure of the knowledge graph rather than biology, so this prediction should be treated as a hypothesis only.
Other predicted indications have somewhat more support and may be better candidates to pursue:
- Congenital hematological disorder (sickle cell disease): Two trials of macrolide or azithromycin therapy for lung complications (NCT02960503 and NCT02630394) were both withdrawn with zero enrollment, so no efficacy data exist. This is the highest evidence level among the predictions (L3).
- Monoclonal gammopathy: A preclinical study (PMID 23546223) showed that macrolides, including azithromycin, block autophagy flux and enhance bortezomib cytotoxicity in myeloma cell lines.
- Septicemic plague: An in vitro study (PMID 8540736) reported poor azithromycin activity against Yersinia pestis, which weakens this prediction.
Clinical Trial Evidence
Currently no related clinical trials registered for hyperamylasemia.
Literature Evidence
Currently no related literature available for hyperamylasemia.
Singapore Market Information
The licence records contain no approved indication text. The main authorizations are:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN10911P | ZITHROMAX TABLET 250 mg | Film-coated tablet | Not specified |
| SIN07863P | ZITHROMAX POWDER FOR ORAL SUSPENSION 200 mg/5 ml | Powder for oral suspension | Not specified |
| SIN12057P | ZITHROMAX IV POWDER FOR SOLUTION FOR INFUSION 500 mg/vial | Powder for solution for infusion | Not specified |
| SIN14040P | AZmycin Tablet 500mg | Film-coated tablet | Not specified |
| SIN16876P | ZITHROTEL POWDER FOR SOLUTION FOR INFUSION 500MG/VIAL | Powder for solution for infusion | Not specified |
All 16 registrations are valid single-ingredient products, available as oral tablets, oral suspension powder and intravenous infusion powder.
Safety Considerations
- Contraindications and risk conditions (from the knowledge graph, not label text): long QT syndrome, familial long QT syndrome, torsades de pointes, liver disease, gallbladder disease, Clostridium difficile colitis, perinatal necrotizing enterocolitis, myasthenia gravis, neuromuscular junction disease, hearing disorder and auditory system disease.
- Drug Interactions: 100 interactions were identified. The major ones are with cisapride and dolasetron, both related to QT prolongation. Many moderate interactions involve antacids (aluminium hydroxide, magnesium salts), laxatives (bisacodyl, castor oil, lactulose, lactitol, glycerin), famotidine, loperamide, clarithromycin, levofloxacin, granisetron and balsalazide. Amoxicillin and metronidazole interactions are minor.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no trials, no literature and no plausible mechanism for hyperamylasemia. Evidence level is L5, and the package insert safety information has not yet been obtained.
To proceed, the following is needed:
- A mechanistic rationale or biological hypothesis linking azithromycin to hyperamylasemia
- Mechanism of action (MOA) data for azithromycin
- Singapore package insert warnings, contraindications and approved indication text
- A QT-risk and drug interaction management plan, given the major interactions
- Consideration of better-supported predicted indications (e.g., sickle cell-related lung complications, or myeloma-related combination research) as alternative candidates
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.